Onconic Therapeutics Inc. (KOSDAQ:476060)

Onconic Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	51,771	47,046	43,000	30,100	27,316	18,861
Trading Asset Securities	5,534	5,689	-	-	-	-
Cash & Short-Term Investments	57,305	52,735	43,000	30,100	27,316	18,861
Cash Growth	28.83%	22.64%	42.85%	10.19%	44.83%	-
Accounts Receivable	17,863	10,531	7,326	-0	841.52	173.71
Other Receivables	117.54	46.21	254.84	366.74	5.08	2.9
Receivables	17,980	10,578	7,581	366.74	846.6	176.61
Prepaid Expenses	22.33	47.24	-	-	-	-
Other Current Assets	455.35	476.7	1,554	291.85	8.22	10.43
Total Current Assets	75,764	63,837	52,134	30,759	28,171	19,048
Property, Plant & Equipment	2,996	3,060	3,285	3,568	2,619	263.6
Other Intangible Assets	-	0.1	1.27	2.45	3.63	4.8
Long-Term Deferred Tax Assets	8,800	8,800	5,355	3,100	-	-
Other Long-Term Assets	27.35	9.25	137.95	118.38	113.14	110.6
Total Assets	87,587	75,707	60,913	37,548	30,907	19,427

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	5,573	2,669	708.67	-	-	-
Accrued Expenses	75.51	75.51	65.56	82.14	-	-
Current Portion of Leases	58.29	81.27	188.95	154.27	50.72	135.52
Current Income Taxes Payable	22.39	22.39	463.39	-	-	-
Other Current Liabilities	2,263	774.07	3,339	42,977	26,539	392.14
Total Current Liabilities	7,992	3,623	4,765	43,214	26,590	527.66
Long-Term Leases	57.14	44.53	119.52	199.4	-	53.52
Pension & Post-Retirement Benefits	13.56	-	9.59	3.8	25.04	-
Other Long-Term Liabilities	-	-	0	25.14	26,229	26,823
Total Liabilities	8,063	3,667	4,895	43,442	52,844	27,405

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	22,444	22,245	5,402	2,890	2,890	2,890
Additional Paid-In Capital	24,041	22,576	87,419	7,146	7,146	7,146
Retained Earnings	33,104	26,682	-39,121	-31,019	-32,688	-18,256
Comprehensive Income & Other	-65.28	536.94	2,319	1,294	715.69	243.21
Total Common Equity	79,524	72,039	56,019	-19,690	-21,937	-7,978
Shareholders' Equity	79,524	72,039	56,019	-5,894	-21,937	-7,978
Total Liabilities & Equity	87,587	75,707	60,913	37,548	30,907	19,427

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	115.43	125.8	308.47	353.66	50.72	189.04
Net Cash (Debt)	57,190	52,609	42,691	29,747	27,265	18,672
Net Cash Growth	29.34%	23.23%	43.52%	9.10%	46.02%	-
Net Cash Per Share	1240.81	1159.65	1305.39	1286.70	1179.32	815.23
Filing Date Shares Outstanding	44.89	44.49	43.22	36.83	23.12	22.9
Total Common Shares Outstanding	44.89	44.49	43.22	36.83	23.12	22.9
Working Capital	67,771	60,214	47,369	-12,454	1,581	18,520
Book Value Per Share	1771.61	1619.23	1296.26	-534.61	-948.83	-348.30
Tangible Book Value	79,524	72,039	56,018	-19,692	-21,941	-7,982
Tangible Book Value Per Share	1771.61	1619.23	1296.23	-534.68	-948.99	-348.51
Land	570.58	570.58	570.58	570.58	-	-
Buildings	1,617	1,617	1,617	1,617	-	-
Machinery	1,550	1,495	1,138	1,033	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 12, 2026

Data Sources Report a data error